Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All cannabidiol studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchCannabidiolCannabidiol (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Symp. case -212% Improvement Relative Risk Symp. case (b) -71% Case -3% Cannabidiol for COVID-19  Merianos et al.  Prophylaxis Is prophylaxis with cannabidiol beneficial for COVID-19? Retrospective 800 patients in the USA More symptomatic cases with cannabidiol (p=0.0000069) c19early.org Merianos et al., Addictive Behaviors, Mar 2022 Favors cannabidiol Favors control

Concurrent use of e-cigarettes and cannabis and associated COVID-19 symptoms, testing, and diagnosis among student e-cigarette users at four U.S. Universities

Merianos et al., Addictive Behaviors, doi:10.1016/j.addbeh.2021.107170
Mar 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Retrospective 800 e-cigarette users in the USA, showing higher risk of COVID-19 diagnosis and symptoms with cannabis use.
risk of symptomatic case, 211.9% higher, RR 3.12, p < 0.001, treatment 94 of 416 (22.6%), control 20 of 384 (5.2%), odds ratio converted to relative risk, COVID-19 symptoms.
risk of symptomatic case, 70.6% higher, RR 1.71, p = 0.008, treatment 77 of 416 (18.5%), control 38 of 384 (9.9%), odds ratio converted to relative risk, COVID-19 diagnosis.
risk of case, 3.4% higher, RR 1.03, p = 0.33, treatment 367 of 416 (88.2%), control 317 of 384 (82.6%), odds ratio converted to relative risk, COVID-19 test.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Merianos et al., 31 Mar 2022, retrospective, USA, peer-reviewed, survey, 6 authors. Contact: ashley.merianos@uc.edu, ar117@uark.edu, melinda.mahabee-gittens@cchmc.org, aebarry@tamu.edu, my10@iu.edu, linhsi@indiana.edu.
This PaperCannabidiolAll
Concurrent use of e-cigarettes and cannabis and associated COVID-19 symptoms, testing, and diagnosis among student e-cigarette users at four U.S. Universities
Ashley L Merianos, Alex M Russell, E Melinda Mahabee-Gittens, Adam E Barry, Meng Yang, Hsien-Chang Lin
Addictive Behaviors, doi:10.1016/j.addbeh.2021.107170
This investigation assessed whether current (past 30-day) electronic cigarette (e-cigarette) and cannabis use was associated with coronavirus disease 2019 (COVID-19) symptomatology, testing, and diagnosis among college student e-cigarette users. Methods: Participants were 18-26-year-old college student e-cigarette users attending four geographically diverse, large U.S. public universities during October-December 2020 (N = 800). Multivariable logistic regression models explored associations between exclusive e-cigarette use and concurrent e-cigarette and cannabis use and COVID-19 symptoms, testing, and diagnosis. Models controlled for demographics, university site, and current use of combustible cigarettes, cigars, and smokeless tobacco. Results: Over half of student e-cigarette users (52.0%) concurrently used cannabis. Compared to exclusive ecigarette users, concurrent e-cigarette and cannabis users were 3.53 times more likely (95%CI = 1.96-6.36) to report COVID-19 symptoms, after adjusting for the covariates. Compared to infrequent exclusive e-cigarette users, infrequent concurrent users (AOR = 4.72, 95%CI = 1.31-17.00), intermediate concurrent users (AOR = 5.10, 95%CI = 1.37-18.97), and frequent concurrent users (AOR = 7.44, 95%CI = 2.06-26.84) were at increased odds of reporting COVID-19 symptoms. Compared to exclusive e-cigarette users, concurrent e-cigarette and cannabis users were 1.85 times more likely (95%CI = 1.15-2.98) to report a COVID-19 diagnosis. Intermediate concurrent users (AOR = 2.88, 95%CI = 1.13-7.35) and frequent concurrent users (AOR = 3.22, 95%CI = 1.32-7.87) were at increased odds of reporting a COVID-19 diagnosis, compared to infrequent exclusive ecigarette users. Conclusions: Concurrent use of e-cigarettes and cannabis may be an underlying risk factor of COVID-19 symptomatology and diagnosis, with more pronounced odds found among intermediate and frequent users. Results highlight the need to educate students about the impacts of e-cigarette and cannabis use on respiratory, immune, and overall health.
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
Amato, Boyle, Levy, How to define e-cigarette prevalence? Finding clues in the use frequency distribution, Tobacco Control, doi:10.1136/tobaccocontrol-2015-052236
Benowitz, Hukkanen, Jacob, Iii, Nicotine chemistry, metabolism, kinetics and biomarkers, Handbook of Experimental Pharmacology, doi:10.1007/978-3-540-69248-5_2
Bhatta, Glantz, Association of e-cigarette use with respiratory disease among adults: A longitudinal analysis, American Journal of Preventive Medicine, doi:10.1016/j.amepre.2019.07.028
Blount, Karwowski, Shields, Morel-Espinosa, Valentin-Blasini et al., Vitamin E acetate in bronchoalveolar-lavage fluid associated with EVALI, New England Journal of Medicine, doi:10.1056/NEJMoa1916433
Borgonhi, Volpatto, Ornell, Rabelo-Da-Ponte, Kessler, Multiple clinical risks for cannabis users during the COVID-19 pandemic, Addict Sci Clin Pract, doi:10.1186/s13722-021-00214-0
Brake, Barnsley, Lu, Mcalinden, Eapen et al., Smoking upregulates angiotensin-converting enzyme-2 receptor: A potential adhesion site for novel coronavirus SARS-CoV-2 (Covid-19), Journal of Clinical Medicine, doi:10.3390/jcm9030841
Braymiller, Barrington-Trimis, Leventhal, Islam, Kechter et al., Assessment of nicotine and cannabis vaping and respiratory symptoms in young adults, JAMA Netw Open, doi:10.1001/jamanetworkopen.2020.30189
Chen, Kyriakos, Cigarette and E-cigarettes dual users, exclusive users and COVID-19: Findings from four UK birth cohort studies, International Journal of Environmental Research and Public Health, doi:10.3390/ijerph18083935
Dong, Du, Gardner, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infectious Diseases, doi:10.1016/S1473-3099(20)30120-1
Gaiha, Cheng, Halpern-Felsher, Association between youth smoking, electronic cigarette use, and coronavirus disease 2019, Journal of Adolescent Health, doi:10.1016/j.jadohealth.2020.07.002
Gates, Jaffe, Copeland, Cannabis smoking and respiratory health: Consideration of the literature, Respirology, doi:10.1111/resp.12298
Gaunkar, Nagarsekar, Carvalho, Jodalli, Mascarenhas, COVID-19 in smokeless tobacco habitués: Increased susceptibility and transmission, Curēus, doi:10.7759/cureus.8824
Ghasemiesfe, Ravi, Vali, Korenstein, Arjomandi et al., Marijuana use, respiratory symptoms, and pulmonary function: A systematic review and meta-analysis, Annals of Internal Medicine, doi:10.7326/M18-0522
Gudnadóttir, Ýr, Ólafsdóttir, Middelveld, Ekerljung et al., An investigation on the use of snus and its association with respiratory and sleep-related symptoms: A cross-sectional population study, BMJ Open, doi:10.1136/bmjopen-2016-015486
Gupta, Nethan, Mehrotra, Tobacco use as a well-recognized cause of severe COVID-19 manifestations, Respiratory Medicine, doi:10.1016/j.rmed.2020.106233
Hsu, Sun, Zhu, Evolution of electronic cigarette brands from 2013-2014 to 2016-2017: Analysis of brand websites, J Med Internet Res, doi:10.2196/jmir.8550
Huestis, Human cannabinoid pharmacokinetics, Chemistry & Biodiversity, doi:10.1002/(ISSN)1612-188010.1002/cbdv.v4:810.1002/cbdv.200790152
Kaur, Lungarella, Rahman, SARS-CoV-2 COVID-19 susceptibility and lung inflammatory storm by smoking and vaping, Journal of Inflammation, doi:10.1186/s12950-020-00250-8
Keith, Bhatnagar, Cardiorespiratory and immunologic effects of electronic cigarettes [published online ahead of print, Curr Addict Rep
Krishnasamy, Hallowell, Ko, Board, Hartnett et al., Update: Characteristics of a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury-United States, MMWR. Morbidity and Mortality Weekly Report, doi:10.15585/mmwr.mm6903e2
Lanza, Motlagh, Orozco, E-cigarette use among young adults: A latent class analysis examining co-use and correlates of nicotine vaping, Addictive Behaviors, doi:10.1016/j.addbeh.2020.106528
Li, Sundar, Mcintosh, Association of smoking and electronic cigarette use with wheezing and related respiratory symptoms in adults: cross-sectional results from the Population Assessment of Tobacco and Health (PATH) study, wave 2, Tob Control, doi:10.1136/tobaccocontrol-2018-054694
Madison, Landers, Gu, Chang, Tung et al., Electronic cigarettes disrupt lung lipid homeostasis and innate immunity independent of nicotine, J Clin Invest, doi:10.1172/JCI12853110.1172/JCI128531DS1
Martinasek, Mcgrogan, Maysonet, A systematic review of the respiratory effects of inhalational marijuana, Respir Care, doi:10.4187/respcare.04846
Mckelvey, Halpern-Felsher, How and why California young adults are using different brands of pod-type electronic cigarettes in 2019: Implications for researchers and regulators, Journal of Adolescent Health, doi:10.1016/j.jadohealth.2020.01.017
Medicine, The EVALI outbreak and vaping in the COVID-19 era, Lancet Resp Med, doi:10.1016/S2213-2600(20)30360-X
Salant, Dillman, How to conduct your own survey
Schulenberg, Johnston, O'malley, Monitoring the Future national survey results on drug use
Statacorp, Statacorp Llc ; Tashkin, Roth, Pulmonary effects of inhaled cannabis smoke, American Journal of Drug and Alcohol Abuse, doi:10.1080/00952990.2019.1627366
Taylor, Wiens, Peterson, Saravia, Lunda et al., Characteristics of e-cigarette, or vaping, products used by patients with associated lung injury and products seized by law enforcement -Minnesota, 2018 and, MMWR. Morbidity and Mortality Weekly Report, doi:10.15585/mmwr.mm6847e1
Temple, Shorey, Lu, Torres, Stuart et al., E-cigarette use of young adults motivations and associations with combustible cigarette alcohol, marijuana, and other illicit drugs, American Journal on Addictions, doi:10.1111/ajad.v26.410.1111/ajad.12530
Traboulsi, Cherian, Abou Rjeili, Preteroti, Bourbeau et al., Inhalation toxicology of vaping products and implications for pulmonary health, International Journal of Molecular Sciences, doi:10.3390/ijms21103495
Volkow, Collision of the COVID-19 and addiction epidemics, Annals of Internal Medicine, doi:10.7326/M20-1212
Xie, Li, Cross-sectional association between lifetime use of electronic cigarettes with or without marijuana and self-reported past 12-month respiratory symptoms as well as lifetime respiratory diseases in U.S. adults, Nicotine Tobacco Res, doi:10.1093/ntr/ntaa194
Yayan, Rasche, Damaging effects of cannabis use on the lungs, Advances in Experimental Medicine and Biology, doi:10.1007/5584_2016_71
Zhao, Aravindakshan, Hilpert, Olmedo, Rule et al., Metal/metalloid levels in electronic cigarette liquids, aerosols, and human biosamples: A systematic review, Environmental Health Perspectives, doi:10.1289/EHP5686
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit